Synchronous and Metachronous Breast Malignancies: A Cross-Sectional Retrospective Study and Review of the Literature

Table 2

Histology and TNM staging (AJCC/UICC) of the tumors at the time of diagnosis: in this table we present prevalences and 𝑃 values referring to chi-square test.

	UBC	1st MBC	2nd MBC	1st SBC	2nd SBC	𝑃
Histology
Ductal invasive carcinoma	65.91% (348/528)	69.23% (27/39)	65% (26/40)	43.75% (7/16)	68.75% (11/16)	0.447
Lobular invasive carcinoma	8.9% (47/528)	15.38% (6/39)	12.5% (5/40)	37.5% (6/16)	6.25% (1/16)	<0.05
Ductal and lobular invasive carcinoma	13.45% (71/528)	7.69% (3/39)	5% (2/40)	12.5% (2/16)	6.25% (1/16)	0.418
Other invasive carcinomas	3.41% (18/528)	2.56% (1/39)	0% (0/40)	0% (0/16)	6.25% (1/16)	0.645
Ductal in situ carcinoma	7.39% (39/528)	5.13% (2/39)	17.5% (7/40)	6.25% (1/16)	6.25% (1/16)	0.212
Lobular in situ carcinoma	0.38% (2/528)	0% (0/39)	0% (0/40)	0% (0/16)	0% (0/16)	0.981
Unknown	0.57% (3/528)	0% (0/39)	0% (0/40)	0% (0/16)	6.25% (1/16)	0.067
Tumor (UICC)
Tis-T1	67.94% (356/524)	68.42% (26/38)	70% (28/40)	62.5% (10/16)	75% (12/16)	0.957
T2	24.43% (128/524)	26.32% (10/38)	22.5% (9/40)	37.5% (6/16)	18.75% (3/16)	0.755
T3-T4	7.63% (40/524)	5.26% (2/38)	7.5% (3/40)	0% (0/16)	6.25% (1/16)	0.806
Lymph nodes (UICC)
N0	66.86% (347/519)	75.68% (28/37)	70% (28/40)	56.25% (9/16)	93.75% (15/16)	0.122
N1	19.27% (100/519)	16.22% (6/37)	15% (6/40)	18.75% (3/16)	6.25% (1/16)	0.690
N2	7.51% (39/519)	2.7% (1/37)	10% (4/40)	12.5% (2/16)	0% (0/16)	0.476
N3	6.36% (33/519)	5.41% (2/37)	5% (2/40)	12.5% (2/16)	0% (0/16)	0.679